Idera Pharma (IDRA) Reports In-Line Q3 Loss; Discontinues IMO-2125 Testing

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) reported Q3 loss of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $4 million versus the consensus estimate of $2 million.

Based on its strategic assessment and prioritization, the Company has discontinued further development of IMO-2125 in hepatitis C virus infection and decided to advance its TLR-targeted programs in infectious diseases, respiratory diseases, hematologic oncology, and additional vaccine adjuvant applications only through licensing and partnering.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c